Cargando…
Characteristics affecting oral anticoagulant therapy choice among patients with non-valvular atrial fibrillation: a retrospective claims analysis
BACKGROUND: Dabigatran is one of the three newer oral anticoagulants (OACs) recently approved in the United States for stroke prevention in non-valvular atrial fibrillation (NVAF) patients. The objective of this study was to identify patient, healthcare provider, and health plan factors associated w...
Autores principales: | AbuDagga, Azza, Stephenson, Judith J, Fu, An-Chen, Kwong, Winghan Jacqueline, Tan, Hiangkiat, Weintraub, William S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4112613/ https://www.ncbi.nlm.nih.gov/pubmed/25034699 http://dx.doi.org/10.1186/1472-6963-14-310 |
Ejemplares similares
-
Comparison of claims vs patient-reported adherence measures and associated outcomes among patients with nonvalvular atrial fibrillation using oral anticoagulant therapy
por: Stephenson, Judith J, et al.
Publicado: (2018) -
Exacerbations among chronic bronchitis patients treated with maintenance medications from a US managed care population: an administrative claims data analysis
por: AbuDagga, Azza, et al.
Publicado: (2013) -
Novel oral Anticoagulants in Non-Valvular Atrial Fibrillation
por: da Silva, Rose M.F.L.
Publicado: (2014) -
Balancing the benefits and harms of oral anticoagulation in non-valvular atrial fibrillation
por: Lindley, Richard I
Publicado: (2021) -
Newer Anticoagulants for Non-Valvular Atrial Fibrillation
por: Harburger, Joseph M., et al.
Publicado: (2012)